Pharmaceuticals, Biotechnology and Life Sciences
The National Cancer Institute (NCI) awarded ATCC, a global player in biological materials management and standards, a contract to distribute a new generation of …
The Swiss-based pharmaceutical major Roche has see a sales growth for the first three quarters of 2016, praising good performance of Tecentriq, it’s anti PD-L1 cancer immunotherapy that was approved for non-small cell lung cancerby the US FDA in May this year.
Eli Lilly and Company announced that FDA has granted approval of LARTRUV (olaratumab injection, 10 mg/mL), in combination with doxorubicin, for the treatment of adults with soft tissue sarcoma (STS) with a histologic subtype for which an anthracycline-containing regimen is appropriate and which is not amenable to curative treatment with radiotherapy or surgery.
International Centre for Genetic Engineering and Biotechnology (ICGEB) and Sun Pharma have announced their new collaboration for development of a dengue vaccine, targeted against all the four serotypes of Dengue virus that cause disease in humans.
The company on Thursday said the Placing Shares are being offered by an accelerated bookbuild. Zeus Capital and N+1 Singer will be acting as joint bookrunners in connection with the Bookbuild, Quantum Pharma has said.
Pfizer will begin shipment of INFLECTRA (infliximab-dyyb) for injection, a biosimilar of REMICADE 1 (infliximab) to wholesalers in the United States (U.S.) in late November 2016.
European Commission (EC) has granted Marketing Authorization of ONIVYDE, also known as nal-IRI or MM-398, for the treatment of metastatic adenocarcinoma of the pancreas, in combination with 5-fluorouracil (5-FU) and leucovorin (LV), in adult patients who have progressed following gemcitabine-based therapy.
FDA approves Roche’s cancer immunotherapy TECENTRIQ (atezolizumab) for people with a specific type of metastatic lung cancer.
GW Pharmaceuticals plc has announced leaving AIM and canceling trading in London, to continue trading only on NASDAQ.
Advanced Oncotherapy , the developer of proton therapy systems for cancer treatment, has announced on Tuesday that planning permission for the Harley Street site was granted.